摘要
目的测定多种恶性肿瘤患者血浆中纤溶酶原激活物抑制剂1(Plasminogen activator inhibitor-1,PAI-1)浓度变化情况,探讨PAI-1血浆含量变化作为恶性肿瘤诊断中的作用。方法收集乳腺癌、肺癌、喉癌血液标本各40例,并以正常人血液标本作对照,用ELISA法检测肿瘤患者及正常对照组血浆中PAI-1的含量,并比较其差异。结果与正常对照组(9.84±4.66 ng/ml)相比,乳腺癌(21.49±10.54 ng/ml),肺癌(15.10±8.55 ng/ml),喉癌(14.03±7.14 ng/ml)患者血浆中PAI-1含量均明显升高,其中乳腺癌组与正常组相比差异极为显著(P<0.01)。结论血浆中PAI-1的浓度升高可作为肿瘤诊断辅助指标,PAI-1可作为肿瘤治疗潜在靶位。
Objective to explore the variation of PAI-1 concentration in blood plasma between normal group and cancer groups. Methods assay the plasma PAI-1 level in both cancer groups and normal group by ELISA. Results PAI-1 levels in plasma of breast cancer groups（21.49±10.54 ng/ml）, lung breast cancer groups（ 15.10 ± 8.55 ng/ml） and larynx cancer groups （14.03 ± 7.14 ng/ml）were higher than that of normal group（9.84 ±4.66 ng/ml）, particularly, the PAI-1 concentration in breast cancer groups significeantly varied （P〈 0. 01 ） to control group. Conclusion PAI -1 maybe can used as a auxiliary marker to detect cancer and PAI-I can be a potential target for tumor therapy.
出处
《中国实验诊断学》
北大核心
2010年第4期536-537,共2页
Chinese Journal of Laboratory Diagnosis
基金
国家自然科学基金资助项目(30770493)
